Cyclic amide-tetrahydroisoquinoline compound
By developing cyclic amide-tetrahydroisoquinoline compounds to regulate ferroptosis, the problem of poor efficacy in existing pancreatic cancer treatments has been solved, achieving significant inhibition of pancreatic cancer cells and expanding the scope of new drugs, making them suitable for large-scale production.
Patent Information
- Application Number
- PCT/CN2025/093937
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for pancreatic cancer are not very effective, offering limited survival benefits to patients. Furthermore, pancreatic cancer is highly invasive and metastatic, and existing drugs are showing significant resistance, leaving a lack of effective treatment options.
To develop a cyclic amide-tetrahydroisoquinoline compound that inhibits ferroptosis by regulating the ferroptosis process, especially by inhibiting ferrophagy, thereby preventing the proliferation of pancreatic cancer cells.
It significantly inhibits the proliferation of pancreatic cancer cells, provides a new treatment option, is suitable for large-scale production, has low toxicity, and has a structure different from existing drugs, thus expanding the range of drugs for the clinical treatment of pancreatic cancer.
Smart Images

Figure CN2025093937_12112026_PF_FP_ABST
Abstract
Description
A cyclic amide-tetrahydroisoquinoline compound Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to a cyclic amide-tetrahydroisoquinoline compound. Background Technology
[0002] Pancreatic cancer is a highly malignant tumor, often referred to as the "king of cancers" due to its difficulty in early diagnosis and extremely poor prognosis. Data shows that the five-year survival rate for pancreatic cancer patients is less than 7%, and the World Health Organization predicts that by 2030, pancreatic cancer mortality may rise to become the second leading cause of cancer death worldwide. Most patients are diagnosed at an advanced stage, with the tumor not only severely infiltrating the local area but also frequently metastasizing to distant sites, which is the core reason for its high mortality rate. Furthermore, the high resistance of pancreatic cancer to existing treatments and the high recurrence rate after surgery further exacerbate the disease's lethality.
[0003] Currently, chemotherapy remains the primary treatment for pancreatic cancer, with gemcitabine being a commonly used drug. Targeted therapies targeting epidermal growth factor receptor (EGFR), angiogenesis, the tumor microenvironment, and hypoxia are also available. However, the efficacy of these treatments is not ideal, and patients experience limited survival benefits. Surgical resection is currently the most effective way to potentially cure pancreatic cancer, but due to its high invasiveness and metastatic potential, even after successful surgery, over 76% of patients experience distant metastases within a short period, resulting in a persistently high recurrence rate.
[0004] Given the limitations of existing treatments, the medical community urgently needs to explore new treatment mechanisms and drug development directions to provide new options for the treatment of pancreatic cancer. Summary of the Invention
[0005] To address the shortcomings of existing technologies, this invention proposes a cyclic amide-tetrahydroisoquinoline compound.
[0006] This invention provides a cyclic amide-tetrahydroisoquinoline compound having the following structure (I):
[0007] Among them, ring A has a cyclic amide structure;
[0008] Z can be any one of O, N, or S atoms;
[0009] X is an O atom or -N-R2, where R2 is a H atom or C atom. 1~12 alkyl, C 1~12 alkylamino, C 1~12 alkoxy, C 1~12 alkyl acyl group, C 1~12alkylamide group, C 1~12 Any one of the alkyl ester groups;
[0010] Y is a C or N atom;
[0011] R1 is Where A1 is any one of C, O, S atoms or -NH, A2, A3, A4, A5 and A6 are either C or N atoms, or the same or different, R 11 It can be monosubstituted or polysubstituted, selected from H atoms, C atoms 1~12 Alkyl group, halogen atom, C 1~12 Alkoxy, C 1~12 Alkylamino, C 1~12 Alkyl group, C 1~12 alkylamide group, C 1~12 It consists of one or more of the following: alkyl ester group, amino group, hydroxyl group, unsubstituted or substituted aromatic ring, and unsubstituted or substituted aliphatic ring.
[0012] Ferroprelation, a newly discovered form of programmed cell death, has shown remarkable efficacy in cancer treatment. The inventors, by regulating the ferroptosis process, have discovered a series of drugs targeting pancreatic cancer cells, providing new options for pancreatic cancer treatment. The cyclic amide-tetrahydroisoquinoline compounds of this invention can regulate ferroptosis by inhibiting ferrophagy through co-activation factor 4 (a nuclear receptor 4). Simultaneously, the cyclic amide structure can effectively chelate iron ions, preventing ferroptosis. Therefore, it significantly inhibits tumor cell proliferation, particularly pancreatic cancer cells. The compound structure provided by this invention differs from existing drug structures on the market, expanding the range of drugs for clinical treatment of pancreatic cancer and making it suitable for large-scale production.
[0013] Furthermore, ring A is an aliphatic ring or an aromatic cyclic amide;
[0014] Z represents either an O or N atom;
[0015] X is -N-R2, where R2 is a H atom or a C atom. 1~3 Alkyl groups;
[0016] Y is a C or N atom;
[0017] R1 is Where A1 is any one of O, S, or -NH, A2, A3, A4, A5, and A6 are either C or N atoms, or the same or different, R 11 It can be monosubstituted or polysubstituted, selected from H atoms, C atoms 1~3 Alkyl group, halogen atom, C 1~3 Alkoxy, C 1~3 Any one or more of alkylamino, amino, hydroxyl, unsubstituted or substituted piperazine, indole, and morpholine.
[0018] Furthermore, ring A is a 4- to 7-membered aliphatic cyclic amide;
[0019] Z represents an O atom;
[0020] X is -N-R2, where R2 is a H atom or a C atom. 1~3 Alkyl groups;
[0021] Y is a C or N atom;
[0022] R1 is Where A1 is an S atom or -NH, A2, A3, A4, A5, and A6 are either C or N atoms, and R 11 It can be monosubstituted or polysubstituted, selected from H atoms, C atoms 1~3 Alkyl group, halogen atom, C 1~3 Alkoxy, C 1~3 One or more of alkylamino, amino, hydroxyl, unsubstituted or substituted piperazine, indole, and morpholine, wherein the substituent of the substituted piperazine is C. 1~6 Alkyl, halogen, C 1~6 Any one of alkoxy, hydroxy, or amino groups.
[0023] Furthermore, ring A is a 4- to 6-membered aliphatic cyclic amide;
[0024] Z represents an O atom;
[0025] X is -N-R2, where R2 is a H atom or a C atom. 1~3 Alkyl groups;
[0026] Y represents a C atom;
[0027] R1 is Where A1 is -NH; A2, A3, A4, A5, and A6 are either C or N atoms, either the same or different; R 11 It can be monosubstituted or polysubstituted, selected from H atoms, C atoms 1~3 One or more of alkyl groups, halogen atoms, unsubstituted or substituted piperazines, and morpholine, wherein the substituent of the substituted piperazine is C. 1~3 Alkyl, C 1~3 Any one of alkoxy, hydroxy, or amino groups.
[0028] Furthermore, the cyclic amide-tetrahydroisoquinoline compound has any one of the following structural formulas:
[0029] Further, the cyclic amide-tetrahydroisoquinoline compound is selected from any one of the above compounds 2, 5, 10, 17, 18, 19, 22, 25, 26, 27, 28, 32, 33, 34, 36, 37, 38, 39, 41, 46, 47, 49, 50, 52, 53, 58, 61, 62, 64, 68, 70, 75, 76, 77, 78, 79, 85, 92, 94, 97, 100, 102, and 104.
[0030] Furthermore, the cyclic amide-tetrahydroisoquinoline compound is selected from any one of the above compounds 2, 17, 18, 19, 26, 28, 32, 39, 41, 46, 47, 49, 52, 62, 64, 85, and 100.
[0031] Furthermore, the cyclic amide-tetrahydroisoquinoline compound is selected from any one of the above compounds 2, 18, 28, 47, 39, 41, 46, 64, and 85.
[0032] Furthermore, the cyclic amide-tetrahydroisoquinoline compound is selected from compound 39 above.
[0033] The following is an exemplary synthetic route for a cyclic amide-tetrahydroisoquinoline compound. In example compound 25, ring A is a 6-membered aliphatic cyclic amide; Z is an O atom; X is -N-R2, R2 is a H atom; Y is a C atom; and R1 is... Where A1 is an S atom, A2 is an N atom, and A3, A4, A5, and A6 are all C atoms, R 11 For substituted piperazines, the substituent is methyl:
[0034] The following is an exemplary synthetic route for the cyclic amide-tetrahydroisoquinoline compound 25:
[0035] The following is a method for preparing example compound 25, including the following steps:
[0036] Compound 1a (0.9-1.1 mmol), TBTU (0.9-1.1 mmol), and K2CO3 (1.4-1.6 mmol) were added sequentially to a round-bottom flask. Dry N,N-dimethylformamide (9-11 mL) was added, and the mixture was stirred at room temperature for 55-68 min. Then, compound 2a (0.9-1.1 mmol) was added, and the mixture was magnetically stirred at 60 °C for 11-13 h. The mixture was then extracted 2-4 times with 130-160 mL of ethyl acetate each time. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The solid obtained by rotary evaporation was purified by column chromatography to obtain a yellow solid, which yielded compound 3a (yield 63-65%).
[0037] Compound 3a (1-1.3 mmol) was added to 4-6 mL of methanol, followed by 1-2 mL of TFA. After stirring at room temperature for 2.5-3 hours, saturated magnesium carbonate solution was added to adjust the pH to around 8. The mixture was then extracted 2-4 times with ethyl acetate, using 130-160 mL each time. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain crude compound 4a. Compound 5a (0.9-1.1 mmol) and DBU (1.0-1.2 mmol) were then added and dissolved in N,N-dimethylformamide (7-10 mL). The mixture was magnetically stirred at 60 °C for 7-9 hours. The mixture was then extracted 2-4 times with ethyl acetate, using 150 mL each time. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The solid obtained by rotary evaporation was purified by column chromatography to obtain a yellow solid, yielding compound 6a (yield 58-60%).
[0038] Compound 6a (0.9-1.1 mmol), compound 7a (0.9-1.1 mmol), cesium carbonate (1.1-1.3 mmol), and Pd(OAc)2 (0.9-1.1 mmol) were added to 9-10 mL of methanol and stirred at 80 °C for 11-12 h. After the reaction was completed, the solid was removed by filtration. The solid was washed 2-4 times with methanol, 9-12 mL each time. The filtrate was then evaporated to dryness and purified by column chromatography to obtain a yellow solid, yielding compound 25 (yield 66-68%).
[0039] In summary, compared with the prior art, the present invention achieves the following technical effects:
[0040] (1) The cyclic amide-tetrahydroisoquinoline compounds provided by this invention can significantly inhibit the proliferation of pancreatic cancer cells;
[0041] (2) The cyclic amide-tetrahydroisoquinoline compounds provided by this invention have low toxicity to organisms;
[0042] (3) The preparation process of the cyclic amide-tetrahydroisoquinoline compounds provided by the present invention is simple and easy to produce on a large scale. Attached Figure Description
[0043] To more clearly illustrate the technical solutions of the embodiments of the present invention, the appendices and drawings used in the embodiments will be briefly introduced below. It should be understood that the appendices and drawings below only show some embodiments of the present invention, and therefore should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these appendices and drawings without creative effort.
[0044] Figure 1 is a statistical graph showing the effect of the compound obtained in Example 39 of this invention on the iron ion concentration in PANC-1 cells;
[0045] Figure 2 is a statistical chart showing the effect of the compound obtained in Example 39 of this invention on the iron ion concentration in PaTu-8988T cells;
[0046] Figure 3 shows the results of acute toxicity tests on the compounds obtained in Examples 35, 39, and 75 of this invention. Detailed Implementation
[0047] To enable those skilled in the art to better understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.
[0048] Example
[0049] The present invention will be further illustrated below with reference to specific embodiments and comparative embodiments. The following specific embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the following embodiments, and are not in particular limited to the types of raw materials used in the following specific embodiments.
[0050] I. The sources of raw materials for the examples and comparative examples are as follows:
[0051] Unless otherwise specified, all raw materials used in the embodiments of this invention are commercially available.
[0052] The preparation method of the cyclic amide-tetrahydroisoquinoline compound in this embodiment of the invention is similar to the synthetic route of compound 25 described above, and includes the following steps:
[0053] The compound cycloamide carboxylic acid derivative (1.0 mmol), TBTU (1.0 mmol), and K2CO3 (1.5 mmol) were added sequentially to a round-bottom flask. Then, dry N,N-dimethylformamide (10 mL) was added, and the mixture was stirred at room temperature for 1 hour. Subsequently, Boc-tetrahydroisoquinoline (compound series 2a) (1.0 mmol) containing an amino or hydroxyl group was added, and the mixture was magnetically stirred at 60 °C for 12 hours. The mixture was then extracted with ethyl acetate (3 × 150 mL, i.e., three extractions with 150 mL of ethyl acetate). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The solid obtained by rotary evaporation was purified by column chromatography to obtain a yellow solid, which yielded compound series 3a (yield 60%–88%).
[0054] Compound 3a series (1.0 mmol) was added to 5 mL of methanol, followed by 1 mL of TFA. After stirring at room temperature for 3 hours, saturated magnesium carbonate solution was added to adjust the pH to about 8. The mixture was then extracted with ethyl acetate (3 × 150 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain crude compound 4a series. Compound 5a series (1.0 mmol) and DBU (1.2 mmol) were then added and dissolved in N,N-dimethylformamide (10 mL). The mixture was magnetically stirred at 60 °C for 8 hours. The mixture was then extracted with ethyl acetate (3 × 150 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The solid obtained by rotary evaporation was purified by column chromatography to obtain a yellow solid, which yielded compound 6a series (yield 59%–77%).
[0055] Compounds 6a series (1.0 mmol), 7a series (1.0 mmol), cesium carbonate (1.2 mmol), and Pd(OAc)2 (1.0 mmol) were added to 10 mL of methanol and stirred at 60 °C for 8 h. After the reaction was completed, the solid was removed by filtration, and the solid was washed with methanol (3 × 10 mL). The filtrate was then evaporated to dryness and purified by column chromatography to obtain a yellow solid, which was the final product.
[0056] The structures of the compounds obtained in Examples 1-104 are as follows:
[0057] Example 1
[0058] The characterization data for Example 1 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J=8.8H z,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz,1H),5.53(s,3H) ,4.51(s,2H),4.49(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.2 4(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0059] Example 2
[0060] The characterization data for Example 2 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,J=8.8Hz,1H),7.6 4(d,J=8.8Hz,,1H),7.51(d,J=8.8Hz,,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz ,1H),5.53(s,3H),4.51(s,2H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.78( t,J=6.0Hz,1H),2.24(t,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0061] Example 3
[0062] The characterization data for Example 3 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J= 8.8Hz,,1H),7.51(d,J=8.8Hz,,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,,1H),6.76(d,J=8.8Hz,1H) ,5.53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t, J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H).
[0063] Example 4
[0064] The characterization data for Example 4 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,,1H),7.51(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,,1H),6.76(d,J=8.8 Hz,1H),5.53(s,3H),4.51(s,2H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6.0Hz ,2H),2.78(t,J=6.0Hz,1H),2.38(d,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H).
[0065] Example 5
[0066] The characterization data for Example 5 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,,1H),7.84(d,J=8.8Hz,1J=8.8Hz,H),7.64( d,J=8.8Hz,,1H),7.24(t,J=8.8Hz,1H),7.21(t,,1H),6.83(d,J=8.8Hz,1H),6.76(d,J=8.8Hz,1H),5.53(s,3 H),4.51(s,2H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2. 78(t,J=6.0Hz,1H),2.35(t,J=6.0Hz,4H),2.27(s,J=6.0Hz,3H),1.57(p,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0067] Example 6
[0068] The characterization data for Example 6 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H), 7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(s,1H) ,5.53(s,2H),4.51(q,J=6.0Hz,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J= 6.0Hz, 4H), 2.79 (t, J = 6.0Hz, 1H), 2.66 (t, J = 6.0Hz, 3H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H).
[0069] Example 7
[0070] The characterization data for Example 7 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J =8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5 .53(s,3H),4.51(s,J=6.0Hz,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H), 2.86(t,J=6.0Hz,4H),2.55(t,J=6.0Hz,2H),2.35(t,J=6.0Hz,4H),2.27(s,3H),1.91(q,J=6.0Hz,2H).
[0071] Example 8
[0072] The characterization data for Example 8 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J= 8.8Hz1H),5.53(s,3H),4.51(s,2H),3.66(t,J=6.0Hz,2H),3.56(t,J=6.0Hz,2H),2.87(t,J= 6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.78(t,J=6.0Hz,1H),2.35(t,J=6.0Hz,4H),2.27(s,3H).
[0073] Example 9
[0074] The characterization data for Example 9 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz ,1H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8. 8Hz,1H),6.64(d,1H),5.53(s,3H),4.51(s,2H),4.00(s,2H),3.66(t,J=6.0Hz,2H),2. 87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.24(t,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0075] Example 10
[0076] The characterization data for Example 10 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.69(s,1H),7.64(d,J=8.8Hz, 1H),7.51(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.29(d,J=8.8Hz,1H),7.24(t,J=8.8Hz ,1H),7.21(d,J=8.8Hz,1H),5.53(s,3H),4.51(d,J=6.0Hz,2H),3.66(t,J=6.0Hz,2H),2 .87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.24(t,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0077] Example 11
[0078] The characterization data for Example 11 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7. 51(d,J=8.8Hz,1H),7.47(d,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7.1 1(d,1H),6.88(t,1H),5.53(d,3H),4.51(s,2H),3.84(s,3H),3.66(s,2H),2.87(t ,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.24(t,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0079] Example 12
[0080] The characterization data for Example 12 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.51 (d,J=8.8Hz,1H),7.47(d,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7.11(t, 1H),6.95(d,1H),5.53(s,3H),5.37(s,1H),4.51(s,2H),3.66(t,J=6.0Hz,2H),2.87 (t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.24(t,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0081] Example 13
[0082] The characterization data for Example 13 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.69(s,1H),7.44(d,J=8.8Hz,1H),7.29(d,J=8.8Hz,1H),7.26(d,J=8.8Hz,2H),7.24(t ,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),5.53(s,2H),4.51(s,2H),4.00(d, J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.79(s,1H).
[0083] Example 14
[0084] The characterization data for Example 14 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.69(s,1H),7.44(d,J =8.8Hz,1H),7.29(d,J=8.8Hz,1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H), 7.21(d,J=8.8Hz,1H),5.53(s,3H),4.51(s,2H),3.66(t,J=6.0Hz,2H),3.45(d,J =6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.78(p,J=6.0Hz,1H),2.38(d,J=6.0Hz,2H).
[0085] Example 15
[0086] The characterization data for Example 15 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.69(s,1H),7.44(d,J =8.8Hz,1H),7.29(d,J=8.8Hz,1H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H), 7.21(d,J=8.8Hz,1H),7.20(d,1H),5.53(s,3H),4.37(t,J=6.0Hz,1H),3.97(s,J =6.0Hz,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0087] Example 16
[0088] The characterization data for Example 16 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15 (s, 1H), 8.04 (d, J = 8.8Hz, 1H), 7.59 (s, 1H), 7.44 (d ,J=8.8Hz,1H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz, 1H),7.20(d,1H),7.04(d,1H),5.53(s,3H),4.37(t,J=6.0Hz,1H),3.97(s,J=6 .0Hz,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0089] Example 17
[0090] The characterization data for Example 17 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.51(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8H z1H),5.53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 1.90 (d, J = 6.0Hz, 2H), 1.59 (p, J = 6.0Hz, 4H), 1.57 (p, J = 6.0Hz, 2H).
[0091] Example 18
[0092] The characterization data for Example 18 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7 .51(d,J=8.8Hz,1H),7.34(d,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7. 17(d,1H),5.53(s,3H),4.51(s,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H) ,2.78(t,J=6.0Hz,1H),2.29(d,J=6.0Hz,3H),2.24(t,2H),1.51(q,J=6.0Hz,2H).
[0093] Example 19
[0094] The characterization data for Example 19 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.69(s,1H),7.44(d,J=8. 8Hz,1H),7.29(d,J=8.8Hz,1H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d ,J=8.8Hz,1H),7.20(d,1H),5.53(s,3H),4.37(d,J=6.0Hz,1H),3.97(s,2H),3.66( t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0095] Example 20
[0096] The characterization data for Example 20 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J =8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz,1H), 4.51(s,2H),4.49(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H), 2.35(t,J=6.0Hz,4H),2.25(s,3H),2.20(t,J=6.0Hz,2H),1.76(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,4H).
[0097] Example 21
[0098] The characterization data for Example 21 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J =8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,3H ),4.51(q,J=6.0Hz,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.47(q,J=6.0Hz,2H),3.27(t,J =6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),1.57(p,J=6.0Hz,2H),1.51(q,J=6.0Hz,2H).
[0099] Example 22
[0100] The characterization data for Example 22 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8 Hz,1H),7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d, 1H),6.76(d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J =6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(s,1H),2.66(s,3H).
[0101] Example 23
[0102] The characterization data for Example 23 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.6 4(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J= 8.8Hz1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0H z,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0103] Example 24
[0104] The characterization data for Example 24 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1 H),7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76 (d,J=8.8Hz1H),5.53(s,3H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3 .56(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H).
[0105] Example 25
[0106] The characterization data for Example 25 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J=8. 8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5.53(s ,3H),4.51(s,2H),4.49(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4 H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H), 2.24 (t, J = 6.0Hz, 2H), 1.78 (q, J = 6.0Hz, 2H), 1.31 (p, J = 6.0Hz, 2H).
[0107] Example 26
[0108] The characterization data for Example 26 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d ,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1 H),5.53(s,3H),4.51(s,2H),4.49(s,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27(t,J=6 .0Hz,4H),2.87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(t,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0109] Example 27
[0110] The characterization data for Example 27 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J= 8.8Hz1H),5.53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J= 6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.35(t,4J=6.0Hz,H),2.27(s,3H),1.90(d,J=6.0Hz,2H).
[0111] Example 28
[0112] The characterization data for Example 28 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64 (d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5 .53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86 (t,J=6.0Hz,4H),2.55(t,J=6.0Hz,2H),2.35(t,J=6.0Hz,4H),2.27(s,3H),1.91(q,J=6.0Hz,2H).
[0113] Example 29
[0114] The characterization data for Example 29 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1 H),7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76 (d,J=8.8Hz1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3 .66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0115] Example 30
[0116] The characterization data for Example 30 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8H z1H),5.53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz, 2H), 3.27(t,J=6.0Hz,4H), 2.87(t,J=6.0Hz,2H), 2.55(t,J=6.0Hz,2H), 1.91(q,J=6.0Hz,2H).
[0117] Example 31
[0118] The characterization data for Example 31 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8H z1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 1.90 (d, J = 6.0Hz, 2H), 1.59 (p, J = 6.0Hz, 4H), 1.57 (p, J = 6.0Hz, 2H).
[0119] Example 32
[0120] The characterization data for Example 32 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d ,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53( s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6 .0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H).
[0121] Example 33
[0122] The characterization data for Example 33 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz ,1H),7.64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H), 6.76(d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),4.00(s,1H),3.67(t,J=6.0Hz,4H),3.6 6(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0123] Example 34
[0124] The characterization data for Example 34 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57 (s, 1H), 8.15 (s, 2H), 8.04 (d, J = 8.8Hz, 1H), 7.84 (d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.24(d,1H),7.21(d,J=8.8Hz,1H), 6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0 Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0125] Example 35
[0126] The characterization data for Example 35 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8H z1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 2.79 (d, J = 6.0Hz, 1H), 1.59 (p, J = 6.0Hz, 4H), 1.57 (p, J = 6.0Hz, 2H).
[0127] Example 36
[0128] The characterization data for Example 36 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz, 1H),7.59(s,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8. 8Hz,1H),7.04(d,1H),6.83(d,1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0 Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0129] Example 37
[0130] The characterization data for Example 37 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz, 1H),7.59(d,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8. 8Hz,1H),7.04(d,1H),6.83(d,1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0 Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0131] Example 38
[0132] The characterization data for Example 38 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7 .59(s,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7. 04(d,1H),6.83(d,1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t, J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0133] Example 39
[0134] The characterization data for Example 39 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d,J= 8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,3H) ,4.51(s,2H),4.49(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H) ,2.35(t,J=6.0Hz,4H),2.27(s,3H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0135] Example 40
[0136] The characterization data for Example 40 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d, J=8.8Hz,1H),7.24(d,1H),7.21(t,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,3H),4.51(s,2H), 4.49(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.24(t,J= 6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0137] Example 41
[0138] The characterization data for Example 41 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.64(d ,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53( s,3H),4.51(s,2H),4.49(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27(t,J=6 .0Hz,4H),2.87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0139] Example 42
[0140] The characterization data for Example 42 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.59(d ,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7.04(d,1H), 6.83(d,1H),5.53(s,3H),4.51(s,2H),4.49(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2. 87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0141] Example 43
[0142] The characterization data for Example 43 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76( d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t, J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.79(d,J=6.0Hz,1H),2.35(t,J=6.0Hz,4H),2.27(s,3H).
[0143] Example 44
[0144] The characterization data for Example 44 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H), 6.76(d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H) ,3.66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0145] Example 45
[0146] The characterization data for Example 45 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76( d,J=8.8Hz1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t, J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.35(t,J=6.0Hz,4H),2.27(s,3H),1.90(d,J=6.0Hz,2H).
[0147] Example 46
[0148] The characterization data for Example 46 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,2H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1 H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz, 1H),6.76(d,J=8.8Hz1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0 Hz, 4H), 3.66 (t, J = 6.0Hz, 2H), 3.27 (t, J = 6.0Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 1.90 (s, 2H).
[0149] Example 47
[0150] The characterization data for Example 47 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H ),7.59(s,1H),7.51(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz, 1H),7.21(d,J=8.8Hz,1H),7.04(d,1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6 .0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0151] Example 48
[0152] The characterization data for Example 48 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.51(d,J= 8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.80(d ,1H),5.53(s,3H),4.51(s,2H),4.49(q,J=6.0Hz,1H),4.00(s,2H),3.66(t,J=6.0Hz,2H), 2.87(t,J=6.0Hz,2H), 2.24(t,J=6.0Hz,2H), 1.78(q,J=6.0Hz,2H), 1.31(p,J=6.0Hz,2H).
[0153] Example 49
[0154] The characterization data for Example 49 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H) ,7.51(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d ,J=8.8Hz,1H),6.80(d,1H),5.53(s,3H),4.51(s,2H),4.00(s,2H),3.66(t,J= 6.0Hz,2H),3.56(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H).
[0155] Example 50
[0156] The characterization data for Example 50 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.24(t,J=8.8Hz, 1H),7.21(d,J=8.8Hz,1H),6.80(d,1H),5.53(s,2H),4.51(s,2H),4.00(s ,3H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0157] Example 51
[0158] The characterization data for Example 51 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.51 (d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz, 1H),6.80(d,1H),5.53(s,3H),4.51(s,2H),4.37(t,J=6.0Hz,1H),4.00(s,2H),3.66 (t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0159] Example 52
[0160] The characterization data for Example 52 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),8.04(d,J=8.8Hz,1H),7.64(d,J=8.8Hz,1H),7.51 (d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz, 1H),6.80(d,1H),5.53(s,3H),4.51(s,2H),4.00(s,2H),3.66(t,J=6.0Hz,2H),2.96 (q,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.00(q,J=6.0Hz,2H).
[0161] Example 53
[0162] The characterization data for Example 53 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8 Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(t,1H),6.76(d,J=8.8Hz1H),5.53(s,2H ),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,2H),3.27(t,J=6.0H z,4H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),1.57(p,J=6.0Hz,,2H),1.51(q,J=6.0Hz,2H).
[0163] Example 54
[0164] The characterization data for Example 54 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8 Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz,1H),5.53(s,2 H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,2H),3.27(t,J=6.0 Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 2.78 (t, J = 6.0Hz, 1H), 1.57 (p, J = 6.0Hz, 2H), 1.51 (q, J = 6.0Hz, 2H).
[0165] Example 55
[0166] The characterization data for Example 55 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51(d,J= 8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8H z1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz, 2H), 3.27(t,J=6.0Hz,4H), 2.87(t,J=6.0Hz,2H), 2.55(t,J=6.0Hz,2H), 1.91(q,J=6.0Hz,2H).
[0167] Example 56
[0168] The characterization data for Example 56 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.4 4(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J =8.8Hz1H),5.53(s,2H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.5 6(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H).
[0169] Example 57
[0170] The characterization data for Example 57 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H), 7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(s,1H),5.53(s,2H),4.51(q,J=6. 0Hz,2H),4.49(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.35( t,J=6.0Hz,4H),2.27(s,J=6.0Hz,3H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0171] Example 58
[0172] The characterization data for Example 58 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz ,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5.53( s,2H),4.51(s,2H),4.49(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27(t,J=6 .0Hz,4H),2.87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0173] Example 59
[0174] The characterization data for Example 59 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44( d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8H z1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6. 0Hz, 2H), 2.86 (t, J = 6.0Hz, 4H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H), 1.90 (d, J = 6.0Hz, 2H).
[0175] Example 60
[0176] The characterization data for Example 60 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8 .8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53( s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t ,J=6.0Hz,4H),2.55(t,J=6.0Hz,2H),2.35(t,J=6.0Hz,4H),2.27(s,3H),1.91(q,J=6.0Hz,2H).
[0177] Example 61
[0178] The characterization data for Example 61 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.4 4(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J =8.8Hz1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.6 6(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0179] Example 62
[0180] The characterization data for Example 62 are as follows: 1 H NMR(400MHz,CD3OD)δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7 .44(d,J=8.8Hz,1H),7.24(d,1H),7.21(t,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.5 3(s,2H),4.51(s,2H),4.37(s,1H),3.67(q,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27 (t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0181] Example 63
[0182] The characterization data for Example 63 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d, J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H) ,5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H ),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H),1.59(t,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H).
[0183] Example 64
[0184] The characterization data for Example 64 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8 .8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53( s,2H),4.51(s,2H),4.37(t,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t ,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,2H).
[0185] Example 65
[0186] The characterization data for Example 65 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.4 4(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J =8.8Hz1H),5.53(s,1H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.6 6(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0187] Example 66
[0188] The characterization data for Example 66 are as follows: 1 H NMR(400MHz,CD3OD)δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8 Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H), 6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,1H),4.51(s,2H),4.00(d,J=6.0 Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0189] Example 67
[0190] The characterization data for Example 67 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d, J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H) ,5.53(s,1H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H ),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H).
[0191] Example 68
[0192] The characterization data for Example 68 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.40(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz, 1H),7.04(d,1H),6.83(d,1H),5.53(s,1H),4.51(s,2H),4.00(d,J=6.0Hz ,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0193] Example 69
[0194] The characterization data for Example 69 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.40(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz, 1H),7.04(d,1H),6.83(d,1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz ,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0195] Example 70
[0196] The characterization data for Example 70 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15 (s, 2H), 7.88 (d, 1H), 7.64 (d, J = 8.8Hz, 1H), 7.44 (d, J=8.8Hz,1H),7.40(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7.04(d ,1H),6.83(d,1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J= 6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0197] Example 71
[0198] The characterization data for Example 71 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8Hz, 1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,2H),4.5 1(s,2H),4.49(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2 .35(t,J=6.0Hz,4H),2.27(s,3H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0199] Example 72
[0200] The characterization data for Example 72 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H ),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,2H),4.51(s, 2H),4.49(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),3.47(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.24(t, J=6.0Hz,2H),1.78(t,J=6.0Hz,2H),1.59(p,J=6.0Hz,4H),1.57(p,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0201] Example 73
[0202] The characterization data for Example 73 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8.8 Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.83(d,1H),6.76(d,J=8.8Hz1H),5.53(s,2H ),4.51(s,2H),4.49(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27(t,J=6.0 Hz, 4H), 2.87 (t, J = 6.0Hz, 2H), 2.24 (t, J = 6.0Hz, 2H), 1.78 (q, J = 6.0Hz, 2H), 1.31 (p, J = 6.0Hz, 2H).
[0203] Example 74
[0204] The characterization data for Example 74 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.44(d,J=8 .8Hz,1H),7.40(s,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),7.04(d,1H), 6.83(d,1H),5.53(s,2H),4.51(s,2H),4.49(s,1H),3.66(t,J=6.0Hz,2H),2.87(t ,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(t,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0205] Example 75
[0206] The characterization data for Example 75 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51(d, J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J= 8.8Hz1H),5.53(s,1H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J= 6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.79(d,J=6.0Hz,1H),2.35(t,J=6.0Hz,4H),2.27(s,3H).
[0207] Example 76
[0208] The characterization data for Example 76 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51( d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76 (d,J=8.8Hz1H),5.53(s,1H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3 .66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0209] Example 77
[0210] The characterization data for Example 77 are as follows: 1 H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51( s,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8H z1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6. 0Hz, 2H), 2.86 (t, J = 6.0Hz, 4H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H), 1.90 (d, J = 6.0Hz, 2H).
[0211] Example 78
[0212] The characterization data for Example 78 are as follows: 1H NMR (400MHz, CD3OD) δ8.39(s,1H),8.15(s,2H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51( d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.76 (d,J=8.8Hz1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3 .66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0213] Example 79
[0214] The characterization data for Example 79 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15 (s, 2H), 7.88 (d, 1H), 7.64 (d, J = 8.8Hz, 1H), 7.51 (d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.40(d,1H),7.24(t,J=8.8Hz,1H), 7.21(d,J=8.8Hz,1H),7.04(d,1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0 Hz,1H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0215] Example 80
[0216] The characterization data for Example 80 are as follows: 1H NMR(400MHz,CD3OD)δ8.15(s,2H),7.95(d,1H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51 (d,J=8.8Hz,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H),6.78(d,1H) ,5.53(s,2H),4.51(s,2H),4.49(q,J=6.0Hz,1H),4.00(s,2H),3.66(t,J=6.0Hz,2H),2. 87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0217] Example 81
[0218] The characterization data for Example 81 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),7.95(d,1H),7.88(d,1H),7.64(d,J=8.8H z,1H),7.51(d,J=8.8Hz,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8 .8Hz,1H),6.78(d,1H),5.53(s,2H),4.51(s,2H),4.00(s,2H),3.66(t,J=6. 0Hz, 2H), 3.56 (t, J = 6.0Hz, 2H), 2.87 (t, J = 6.0Hz, 2H), 2.78 (t, J = 6.0Hz, 1H).
[0219] Example 82
[0220] The characterization data for Example 82 are as follows: 1 H NMR (400MHz, CD3OD) δ8.15(s,2H),7.95(d,1H),7.88(d,1H),7.64(d,J=8.8Hz,1H),7.51(d,J=8.8Hz,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7. 21(d,J=8.8Hz,1H),6.78(d,1H),5.53(s,1H),4.51(s,2H),4.00(s,s,d, 3H), 3.66(t,J=6.0Hz,2H), 2.87(t,J=6.0Hz,2H), 2.79(d,J=6.0Hz,1H).
[0221] Example 83
[0222] The characterization data for Example 83 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),7.95(d,1H),7.88(d,1H),7.64(d,J=8.8Hz,1H) ,7.51(d,J=8.8Hz,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H), 6.78(d,1H),5.53(s,2H),4.51(s,2H),4.37(q,J=6.0Hz,1H),4.00(s,2H),3.66(t ,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0223] Example 84
[0224] The characterization data for Example 84 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),7.95(d,1H),7.88(d,1H),7.64(d,J=8.8Hz,1H) ,7.51(d,J=8.8Hz,1H),7.31(t,1H),7.24(t,J=8.8Hz,1H),7.21(d,J=8.8Hz,1H), 6.78(d,1H),5.53(s,2H),4.51(s,2H),4.00(s,2H),3.66(t,J=6.0Hz,2H),2.96(q ,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.00(q,J=6.0Hz,2H).
[0225] Example 85
[0226] The characterization data for Example 85 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8H z,1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J= 8.8Hz1H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.6 6(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.85(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0227] Example 86
[0228] The characterization data for Example 86 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5 .53(s,3H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.45(t,J=6.0Hz,2H) ,3.27(t,J=6.0Hz,4H),2.85(t,J=6.0Hz,2H),2.78(p,J=6.0Hz,1H),2.38(d,J=6.0Hz,2H).
[0229] Example 87
[0230] The characterization data for Example 87 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H),6.76(d,J =8.8Hz1H),5.53(s,3H),4.37(q,J=6.0Hz,1H),3.97(s,J=6.0Hz,2H),3.67(t,J=6.0Hz,4H) ,3.66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0231] Example 88
[0232] The characterization data for Example 88 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1 H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H),6.76 (d,J=8.8Hz1H),5.53(s,2H),4.00(d,J=6.0Hz,1H),3.97(s,2H),3.67(t,J=6.0Hz,4H),3 .66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H),2.87(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0233] Example 89
[0234] The characterization data for Example 89 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5 .53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H) ,3.27(t,J=6.0Hz,4H),2.85(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0235] Example 90
[0236] The characterization data for Example 90 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5 .53(s,3H),4.51(s,2H),3.67(t,J=6.0Hz,4H),3.66(t,J=6.0Hz,2H),3.27(t,J=6.0Hz,4H) ,2.96(q,J=6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.00(q,J=6.0Hz,2H).
[0237] Example 91
[0238] The characterization data for Example 91 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.2 6(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5.53(s,3H) ,4.51(s,2H),4.37(q,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.85(t,J=6.0H z,2H),2.55(t,J=6.0Hz,2H),2.35(t,J=6.0Hz,4H),2.27(d,J=6.0Hz,3H),1.91(q,J=6.0Hz,2H).
[0239] Example 92
[0240] The characterization data for Example 92 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5.53(s ,3H),4.51(s,2H),3.66(q,J=6.0Hz,2H),2.96(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.85(t, J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.35(t,J=6.0Hz,4H),2.27(s,3H),2.00(q,J=6.0Hz,2H).
[0241] Example 93
[0242] The characterization data for Example 93 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1 H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1 H),5.53(s,2H),4.51(s,2H),4.00(d,J=6.0Hz,1H),3.66(t,J=6.0Hz,2H),2.86(t,J=6.0 Hz, 4H), 2.85 (t, J = 6.0Hz, 2H), 2.79 (d, J = 6.0Hz, 1H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H).
[0243] Example 94
[0244] The characterization data for Example 94 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.76(d,J=8.8Hz1H),5. 53(s,3H),4.51(s,2H),3.66(t,2H),3.45(t,J=6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.85(t,J= 6.0Hz, 2H), 2.78 (p, J = 6.0Hz, 1H), 2.38 (d, J = 6.0Hz, 2H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (s, 3H).
[0245] Example 95
[0246] The characterization data for Example 95 are as follows: 1H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H) ,7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H),6.76(d,J= 8.8Hz1H),5.53(s,3H),4.37(q,J=6.0Hz,1H),3.97(s,2H),3.66(t,J=6.0Hz,2H),2.87(t,J= 6.0Hz,2H),2.86(t,J=6.0Hz,4H),2.35(t,J=6.0Hz,4H),2.27(s,3H),1.90(d,J=6.0Hz,2H).
[0247] Example 96
[0248] The characterization data for Example 96 are as follows: 1 H NMR (400MHz, CD3OD) δ8.57(s,1H),8.15(s,1H),8.04(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7 .26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H),6.76(d,J=8.8H z1H),5.53(s,2H),4.00(d,J=6.0Hz,1H),3.97(s,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz, 2H), 2.86 (t, J = 6.0Hz, 4H), 2.79 (d, J = 6.0Hz, 1H), 2.35 (t, J = 6.0Hz, 4H), 2.27 (d, J = 6.0Hz, 3H).
[0249] Example 97
[0250] The characterization data for Example 97 are as follows: 1H NMR (400MHz, CD3OD) δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J =8.8Hz,1H),6.80(d,1H),5.53(s,2H),4.51(s,2H),4.00(s,s,d,3H),3.66(t,J=6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.79(d,J=6.0Hz,1H).
[0251] Example 98
[0252] The characterization data for Example 98 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t, 1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.80(d ,1H),5.53(s,3H),4.51(s,2H),4.00(s,2H),3.66(t,J=6.0Hz,2H),3.45(t,J= 6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.78(q,J=6.0Hz,1H),2.38(d,J=6.0Hz,2H).
[0253] Example 99
[0254] The characterization data for Example 99 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31( t,1H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7. 20(d,1H),6.80(d,1H),5.53(s,3H),4.37(q,J=6.0Hz,1H),4.00(s,2H),3.9 7(s,2H),3.66(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.90(d,J=6.0Hz,2H).
[0255] Example 100
[0256] The characterization data for Example 100 are as follows:1 H NMR (400MHz, CD3OD) δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8H z,1H),7.20(d,1H),6.80(d,1H),5.53(s,2H),4.00(s,s,d3H),3.97(s, 2H), 3.66(t,J=6.0Hz,2H), 2.87(t,J=6.0Hz,2H), 2.79(d,J=6.0Hz,1H).
[0257] Example 101
[0258] The characterization data for Example 101 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t, 1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.80(d ,1H),5.53(s,3H),4.51(s,2H),4.37(q,J=6.0Hz,1H),4.00(s,2H),3.66(t,J= 6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0259] Example 102
[0260] The characterization data for Example 102 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t, 1H),7.26(d,J=8.8Hz,2H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),6.80(d ,1H),5.53(s,3H),4.51(s,2H),4.00(s,2H),3.66(t,J=6.0Hz,2H),2.96(q,J= 6.0Hz,2H),2.85(t,J=6.0Hz,2H),2.78(t,J=6.0Hz,1H),2.00(q,J=6.0Hz,2H).
[0261] Example 103
[0262] The characterization data for Example 103 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H) ,7.26(d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H), 6.80(d,1H),5.53(s,3H),4.37(q,J=6.0Hz,1H),4.00(s,2H),3.97(s,2H),3.66(t ,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),2.55(t,J=6.0Hz,2H),1.91(q,J=6.0Hz,2H).
[0263] Example 104
[0264] The characterization data for Example 104 are as follows: 1 H NMR(400MHz,CD3OD)δ8.15(s,1H),8.04(d,J=8.8Hz,1H),7.47(d,1H),7.31(t,1H),7.26 (d,J=8.8Hz,1H),7.24(t,J=8.8Hz,2H),7.21(d,J=8.8Hz,1H),7.20(d,1H),6.80(d,1H) ,5.53(s,3H),4.49(q,J=6.0Hz,1H),4.00(s,2H),3.97(s,2H),3.66(t,J=6.0Hz,2H),2. 87(t,J=6.0Hz,2H),2.24(t,J=6.0Hz,2H),1.78(q,J=6.0Hz,2H),1.31(p,J=6.0Hz,2H).
[0265] Example 105
[0266] Preparation of injection solution
[0267] Compound 1 prepared in Example 1 was dissolved in a small amount of DMSO, and then water for injection was added according to standard procedures. After fine filtration, the solution was filled, sealed, and sterilized to prepare an injection solution.
[0268] Example 106
[0269] Preparation of tablets
[0270] Compound 1 prepared in Example 1 was granulated and compressed into tablets with cyclodextrin at a weight ratio of 6:1 to obtain tablets.
[0271] Example 107
[0272] Preparation of capsules
[0273] Compound 1 prepared in Example 1 was mixed with microcrystalline cellulose in a weight ratio of 6:1 to form capsules.
[0274] Example 108
[0275] Test the inhibitory effect of the compounds in Examples 1-104 on pancreatic cancer cells.
[0276] 1. Experimental Methods
[0277] Cell source: The cell lines used in this study are human pancreatic cancer cells PANC-1 and PaTu-8988T, derived from ATCC.
[0278] Cell culture: Cells were cultured at 37°C in a 5% CO2 incubator. After being removed from the cryovial, cells were thawed as quickly as possible in a 37°C water bath and immediately placed in 20% fetal bovine serum-modified IMDM medium, with 10 μg / mL of DNASE I added. Cells were centrifuged at 1500 rpm for 5 minutes and then resuspended in complete culture medium at a concentration of 2-5 × 10⁻⁵. 6 Cells / mL; Thawed cells were then cultured in complete medium supplemented with 10% fetal bovine serum (FBS) and BIT (bovine serum albumin 4 g / L, insulin 5 μg / mL, transferrin 60 μg / mL, all from Sigma-Aldrich). To promote cell growth and maintenance, specific cytokines and components were added: 50 ng / mL FLT3 ligand, 10 ng / mL IL-6, 50 ng / mL stem cell factor (SCF), 25 ng / mL thrombopoietin (TPO), 10 ng / mL IL-3, and 10 ng / mL granulocyte colony-forming factor (G-CSF). In addition, the medium also contained 50 μM β-mercaptoethanol (Sigma-Aldrich).
[0279] Test method: Cell death rate was detected using the MTT assay, with cells at a rate of 1×10⁻⁶. 5 / mL was inoculated into H4230 medium, and 10% IMDM was added to the medium. The cells were divided into control group and drug group, and the drug concentration was 1μM. On the second day, 10μL of prepared MTT solution was added to each well and incubated in an incubator at 37℃ for 4h. Then the liquid in the well was carefully discarded, and 120μL of dimethyl sulfoxide was added to each well. The cells were shaken on a shaker for 15min and the absorbance at 492nm was detected by microplate reader.
[0280] 2. Experimental Results
[0281] Table 1. Inhibitory activity of the compounds in the examples against the growth of pancreatic cancer cells.
[0282] L-CFU analysis showed that all compounds prepared in Examples 1-104 inhibited the formation of pancreatic cancer cell colonies. Among them, the compounds prepared in Examples 2, 18, 28, 47, 39, 41, 46, 64, and 85 showed better effects in reducing the formation of pancreatic cancer cell colonies (Table 1). The compound prepared in Example 39 had the best overall effect. Further tests were conducted on the compound of Example 39 (hereinafter referred to as compound 39) as follows:
[0283] Example 109
[0284] Test the effect of compound 39 on intracellular iron ion levels
[0285] 1. Experimental Methods
[0286] Intracellular Fe 2+ Level assay: PANC-1 and PaTu-8988T cells were seeded in 96-well laser confocal microscopy plates, with 5000 cells per well in 100 μL of medium. After overnight incubation, the old medium was discarded, and the cells were treated with medium containing 0.5 μM compound 39 for 6 hours. A probe working solution containing 1 μM FerroOrange and 1 μg / mL Hoechst 33342 was prepared using serum-free medium and added to the 96-well plates. The cells were incubated at 37°C for 30 min, followed by washing with 1×PBS once. Cell analysis was performed using an FV3000 laser confocal microscope or a Cellmics ArrayScan Vti high-content system.
[0287] 2. Experimental Results
[0288] The results showed that compound 39 could significantly reduce the concentration of iron ions in pancreatic cancer cells (Figures 1 and 2).
[0289] Example 110
[0290] Acute toxicity tests of compounds 39, 35, and 75
[0291] 1. Experimental Methods
[0292] SPF-grade C57BL / 6 mice (6-7 weeks old) were used in the experiment and housed in an SPF-grade animal facility at a temperature of 21-24℃ and a humidity of 50-70%. They were fed SPF-grade mouse feed and provided with sterile water. After one week of housekeeping in the animal facility, no abnormalities were observed. The mice were then randomly divided into 6 groups (control group, 39-100mg / kg, 39-200mg / kg, 39-400mg / kg, 35-400mg / kg, and 75-400mg / kg), with 6 mice in each group, half male and half female, and housed in separate cages. 39-100mg / kg, 39-200mg / kg, and 39-400mg / kg represent the dosage of compound 39, 35-400mg / kg represents the dosage of compound 35, and 75-400mg / kg represents the dosage of compound 75.
[0293] The mice were fasted for 12 hours before administration, but allowed free access to water. The mice were then administered the drug by gavage, and were fed normally 4 hours after administration. Within one week of administration, the mice were weighed on days 0, 3, 5, and 7, and any abnormal behavior or death was observed.
[0294] 2. Experimental Results
[0295] As shown in Figure 3, compared with the control group, the mice in the drug-treated group did not show significant changes in body weight, nor did they exhibit acute toxicity symptoms such as death, abnormal behavior, or decreased appetite.
[0296] Based on the test data on the inhibitory effect of cyclic amide-tetrahydroisoquinoline compounds on pancreatic cancer cells, their influence on intracellular iron ion levels, and acute toxicity, it is sufficient to demonstrate that the cyclic amide-tetrahydroisoquinoline compounds prepared by Examples 1-104 have a significant inhibitory effect on pancreatic cancer cells and low toxicity to organisms. This not only expands the types of drugs available for clinical treatment of pancreatic cancer but also makes them suitable for large-scale production.
[0297] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A cyclic amide-tetrahydroisoquinoline compound, characterized by, The compound has the following formula (I): wherein ring A is a cyclic amide structure; Z is any one of O, N or S atom; X is any one of an O atom or -N-R2, wherein R2is an H atom, a C 1~12 alkyl group, a C 1~12 alkylamino group, a C 1~12 alkoxy group, a C 1~12 alkanoyl group, a C 1~12 alkanoylamido group, or a C 1~12 alkanoyloxy group; Y is C or N atom; R1 is wherein A1is any one of C, O, S atom or -NH, A2, A3, A4, A5and A6are the same or different C or N atom, R 11 is mono- or poly-substituted, selected from H atom, C 1~12 alkyl group, halogen atom, C 1~12 alkoxy group, C 1~12 alkylamino group, C 1~12 alkanoyl group, C 1~12 alkanoylamido group, C 1~12 alkyl ester group, amino group, hydroxyl group, non-substituted or substituted aromatic ring, non-substituted or substituted aliphatic ring.
2. The compound of claim 1, wherein ring A is a cyclic amide structure; Z is O or N atom; X is -N-R2, wherein R2is a H atom or a C 1~3 alkyl group; Y is C or N atom; R1 is wherein A1 is any one of O, S atom or -NH, A2, A3, A4, A5 and A6 are the same or different C or N atom, R 11 is mono- or poly-substituted, selected from H atom, C 1~3 alkyl group, halogen atom, C 1~3 alkoxy group, C 1~3 alkylamino group, amino group, hydroxyl group, any one or more of unsubstituted or substituted piperazine, indole, morpholine.
3. The compound of claim 2, wherein ring A is a 4-7 membered aliphatic cyclic amide; Z is O atom; X is -N-R2, wherein R2is a H atom or a C 1~3 alkyl group; Y is C or N atom; R1 is wherein A1 is an S atom or -NH, A2, A3, A4, A5 and A6 are the same or different C or N atoms, R 11 is mono- or polysubstituted and is selected from the group consisting of H atoms, C 1~3 alkyl groups, halogen atoms, C 1~3 alkoxy groups, C 1~3 alkyl groups, halogen, C 1~6 alkyl groups, halogen, C 1~6 alkoxy groups, hydroxyl groups or amino groups.
4. The compound of claim 3, wherein ring A is a 4-6 membered aliphatic cyclic amide; Z is O atom; X is -N-R2, wherein R2is a H atom or a C 1~3 alkyl group; Y is C atom; R1 is wherein A1 is -NH; A2, A3, A4, A5 and A6 are the same or different C or N atoms, R 11 is mono- or poly-substituted, selected from one or more of H atoms, C 1~3 alkyl groups, halogen atoms, non-substituted or substituted piperazine, morpholine, wherein the substituents of the substituted piperazine are C 1~3 alkyl groups, C 1~3 alkoxy groups, hydroxyl groups or amino groups.
5. The compound of claim 1, wherein The cyclic amide-tetrahydroisoquinoline compounds have any one of the following structural formulae:
